Activity and safety of SHR3680, a novel antiandrogen, in patients with metastatic castration-resistant prostate cancer: a phase I/II trial

Xiaojian Qin1†, Dongmei Ji2†, Weijie Gu1†, Weiqing Han3, Hong Luo4, Chuanjun Du5, Qing Zou6, Zhongquan Sun7, Chaozhong He8, Shaoxing Zhu9, Tie Chong10, Xin Yao11, Ben Wan12, Xinfeng Yang13, Aobing Bai13, Chunlei Jin13, Jianjun Zou13 and Dingwei Ye1*

Abstract

Background: Antagonizing the androgen-receptor (AR) pathway is an effective treatment strategy for patients with metastatic castration-resistant prostate cancer (CRPC). Here, we report the results of a first-in-human phase 1/2 study which assessed the safety, pharmacokinetics, and activity of SHR3680 (a novel AR antagonist) in patients with metastatic CRPC.

Methods: This phase 1/2 study enrolled patients with progressive metastatic CRPC who had not been previously treated with novel AR-targeted agents. In the phase 1 dose-escalation portion, patients received oral SHR3680 at a starting daily dose of 40 mg, which was subsequently escalated to 80 mg, 160 mg, 240 mg, 360 mg, and 480 mg per day. In phase 2 dose-expansion portion, patients were randomized to receive daily dose of 80 mg, 160 mg, or 240 mg of SHR3680. The primary endpoint in phase 1 was safety and tolerability and in phase 2 was the proportion of patients with a prostate-specific antigen (PSA) response (≥ 50% decrease of PSA level) at week 12.

Results: A total of 197 eligible patients were enrolled and received SHR3680 treatment, including 18 patients in phase 1 and 179 patients in phase 2. No dose-limiting toxicities were reported and the maximum tolerated dose was not reached. Treatment-related adverse events (TRAEs) occurred in 116 (58.9%) patients, with the most common one being proteinuria (13.7%). TRAEs of grade ≥ 3 occurred in only 23 (11.7%) patients, and no treatment-related deaths occurred. Antitumor activities were evident at all doses, including PSA response at week 12 in 116 (58.9%) patients, prostate-specific antigen (PSA) response (≥ 50% decrease of PSA level) at week 12 in 134 (68.0%; 95% CI, 61.0–74.5) patients, stabilized bone disease at week 12 in 174 (88.3%; 95% CI, 87.2–95.5) patients, and responses in soft tissue lesions in 21 (34.4%, 95% CI, 22.7–47.7) of 61 patients.

Conclusion: SHR3680 was well tolerated and safe, with promising anti-tumor activity across all doses tested in patients with metastatic CRPC. The dose of 240 mg daily was recommended for further phase 3 study.

Trial registration: Clinicaltrials.gov NCT02691975; registered February 25, 2016.

*Correspondence: dwyeli@163.com
†Xiaojian Qin, Dongmei Ji, and Weijie Gu contributed equally to this work.
1 Department of Urology, Fudan University Shanghai Cancer Center, 270 Dong’an Road, Shanghai 200032, China

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
Prostate cancer ranks the second most commonly occurred malignancy and the fifth leading cause of cancer-related death in men, accounting for 14.1% of total newly diagnosed cancer and 6.8% of total cancer death in men worldwide [1]. The growth of prostate cancer cells is androgen-dependent and castration therapy is used as the initial treatment for patients with advanced prostate cancer [2]. However, nearly all castrated patients will inevitably develop castration-resistant prostate cancer (CRPC), mainly due to the persistent activation of androgen receptor (AR) signaling pathway [3–5].

The approvals of two second-generation of AR antagonists enzalutamide and apalutamide in the treatment of CRPC by FDA have greatly revolutionized the treatment paradigm of this disease [6–9]. Despite of promising benefits, some patients do not respond to the approved drugs or only have limited response duration. On the other hand, the risk of seizure is considered as a main safety issue of the second-generation of AR antagonists, which may be attributed to the off-target inhibition of γ-aminobutyric acid (GABAa) receptor by drugs penetrated through the blood-brain barrier [10, 11]. SHR3680, a novel AR antagonist, preclinically displayed comparable anti-tumor potency but with much less distribution in the brain and significantly decreased risk to induce seizure compared with enzalutamide. Based on this context, we conducted this first-in-human phase 1/2 study to assess the safety, pharmacokinetics (PK), and activity of SHR3680 in patients with metastatic CRPC.

Methods
Study design and participants
This was a multicenter trial with a phase 1 dose-escalation portion and a phase 2 dose-expansion portion, which recruited patients at 11 hospitals in China (Additional file 1: Table S1). This trial is registered with ClinicalTrials.gov, number NCT02691975.

Eligible patients were men aged 18–80 years, had histological diagnosis of prostatic adenocarcinoma, progressed on (or were intolerant to or unwilling to receive) previous docetaxel-containing chemotherapy, had a castrate level of testosterone \( \leq 50 \text{ng/dL} \) or 1.73 nmol/L, had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, had a life expectancy of at least 6 months, and had adequate organ function. Disease progression was defined as meeting at least one of prostate-specific antigen (PSA) progression (\( \geq 3 \) rising PSA levels with an interval of \( \geq 1 \) week and the last results of \( \geq 2 \text{ng/mL} \)), soft tissue progression according to Response Evaluation Criteria in Solid Tumors (RECIST) guidelines v1.1, or bone disease progression according to Prostate Cancer Working Group (PCWG2) criteria despite androgen-deprivation therapy. Key exclusion criteria included prior treatment with second-generation of AR antagonists, abiraterone acetate, or ketoconazole; prior history of seizure or diseases that predispose to seizure.

Procedures
In the phase 1 dose-escalation portion, patients were sequentially assigned to different doses to determine the maximum tolerable dose (MTD) in a 3+3 design. Patients received oral SHR3680 at a starting daily dose of 40 mg, which was subsequently escalated to 80 mg, 160 mg, 240 mg, 360 mg, and 480 mg per day. Each cycle contained 28 days of continuous administration. Three or six patients were included in each dose group. If dose-limiting toxicity (DLT) occurred in one of the first three patients in a certain dose group, three more patients would be further enrolled; if one more patient had DLT, escalation to higher dose was terminated, and MTD was defined as the previous dose.

The phase 2 portion contained two stages of dose-expansion. In the first stage, patients were randomized to receive 80 mg, 160 mg, and 240 mg per day of SHR3680, with 33–36 patients in each dose group. Afterwards, 160 mg and 240 mg per day were further selected for use in the second stage of dose-expansion, and 35–45 additional patients were randomized to each group. Randomization was conducted using clinical trial randomized grouping system of Nanjing Medical University. The doses for expansion were selected on the basis of tolerability, safety, and PK of each dose by investigator and funder. Randomization were stratified by prior chemotherapy (yes vs no) and number of bone metastases (\( \leq 5 \) vs \( > 5 \)).

Treatment was continued until radiographic progression, unacceptable toxicity, investigator decision, or withdrawal of consent, whichever occurred first. For patients who experienced a grade \( \geq 3 \) hematological adverse event (AE) or a grade \( \geq 2 \) nonhematological adverse event toxicity that is attributed to the study drug, treatment could be interrupted. When the toxicity recovered to grade \( \leq 1 \), treatment could be resumed at the original...
dose (40 mg per day) or a lower dose. For patients with treatment interruption > 14 days, the treatment must be discontinued.

Assessment
PSA measurements were performed on days 15 and 28 of cycle 1, on days 28 of cycle 2–6, once every 3 cycles thereafter. PSA progression should be confirmed by a second PSA level measurement at least 3 weeks later. Soft tissue response was evaluated according to RECIST v1.1 using CT or MRI, and the first complete response (CR) or partial response (PR) required confirmation 4 weeks later. Radiological assessments were conducted every 3 treatment cycles. Bone disease was assessed according to PCWG2 criteria using radionuclide bone scan. AEs were graded based on the Common Terminology Criteria for Adverse Events, v4.03. After discontinuation of treatment, patients were followed up every 3 months to assess survival and AE assessment were further performed within 30 days after the last administration.

A total of 42 patients were involved in PK analysis, including 18 patients from dose-escalation portion (3 patients in each dose group) and 24 patients from dose-expansion portion (80 mg, 160 mg, and 240 mg per day; 8 patients in each group). A single dose of SHR3680 was firstly given on day 1 and continuous daily dosing was started from day 8. Blood samples were collected at pre-dose, after the single dose, and during the continuous administration period of SHR3680 for PK analysis. Samples were shipped frozen, and the SHR3680 concentration was analyzed using liquid chromatography-tandem mass spectrometry.

Outcomes
The primary endpoints were DLT, MTD, and proportion of patients with a PSA response (defined as a decrease of ≥ 50% in PSA from baseline) at week 12. The secondary endpoints included proportion of patients with a PSA response during the treatment, the best changes of PSA level from baseline, time to PSA progression, objective response rate (ORR, proportion of patients whose best overall response was complete or partial response according to RECIST v1.1), disease control rate (DCR, proportion of patients whose best overall response was complete response, partial response, or stable disease according to RECIST v1.1), radiological progression-free survival (PFS, defined as time from first dose until soft-tissue disease progression [RECIST v1.1], bone lesion progression [PCWG2 criteria], or death, whichever occurred first), overall survival (OS, the time from first dose to death from any cause), time to first subsequent therapy (TFST), proportion of patients with stable disease in bone at week 12, safety, and PK.

Statistical analysis
No hypothesis test for this study. For dose-escalation part (phase 1), the sample size was determined according to the dose-escalation rules of 3+3. For dose expansion part (phase 2), the sample size for each dosage (80 mg, 160 mg, and 240 mg per day) was 33–36 at stage 1 and additional 35–45 patients added for each 160 mg and 240 mg per day dosage at stage 2. Efficacy (except ORR and DCR) and safety were assessed in a population which consisted of all patients who received at least one dose of SHR3680 treatment. ORR and DCR were assessed based on the population who had measurable disease at baseline. PK was analyzed in patients with sufficient number of data points for determining drug concentration or PK parameters.

PSA response rate at week 12, proportion of patients with stable disease in bone at week 12, ORR, and DCR were presented with their corresponding 95% CIs calculated using Clopper-Pearson method. Median time to PSA progression, TFST, PFS, and OS were estimated with the Kaplan-Meier method, and their accompanying 95% CIs were calculated using Brookmeyer-Crowley method. Statistical analyses of efficacy and safety were performed using the SAS software (v9.4), and PK analysis for all parameters was performed using Phoenix WinNonlin (v8.0 or higher).

Results
Patients
Between March 28, 2016, to October 5, 2018, 246 patients were screened for eligibility and 197 patients were enrolled, including 18 patients (3 patients in each dose group) in dose-escalation portion and 179 patients in dose-expansion portion. All the 197 patients received at least one dose of SHR3680 treatment. ORR and DCR were assessed based on the population who had measurable disease at baseline included in full analysis population and safety analysis population (Fig. 1).

As of data cutoff on March 01, 2020, with a median follow-up of 19.2 months (range, 1.3–43.7), the duration of exposure to SHR3680 was 9.0 months (range, 0.2–40.4; Additional file 1: Table S2). A total of 165 (83.8%) patients discontinued from SHR3680 treatment, with disease progression (84/197, 42.6%) being the primary reason for treatment discontinuation. The Kaplan-Meier estimates of median TFST was 12.7 months (95% CI, 10.6–16.1). Baseline demographics and clinical characteristics are presented in Table 1. Among the 197 patients enrolled, median age was 67.0 years (range, 45–80) and 136 (69.0%) patients had an ECOG performance status of 1. The median PSA level at baseline was 66.1 ng/mL (range, 2.7–4796.0). A total of 135 (68.5%) patients had >5 lesions of bone metastases and 36 (18.3%) patients developed
visceral metastases. As to the prior therapy, 82 (41.6%) patients had received prior chemotherapy, 50 (25.4%) had received radiotherapy, and 58 (29.4%) had a history of surgery for primary prostate cancer.

Safety
In the 18 patients enrolled in the dose-escalation phase 1 portion, no protocol-defined DLTs were reported. Therefore, MTD was not reached.

A total of 186 (94.4%) of the 197 patients among the six dose groups experienced at least one AE of any cause. Among them, AEs in 116 (58.9%) patients were considered as treatment-related, and no dose-related trends were noted for any treatment-related adverse event (TRAE; Table 2, Additional file 1: Table S3). The most common treatment-related adverse events (TRAEs) were proteinuria (27 patients, 13.7%), hot flush (22 patients, 11.2%), and decreased white blood cell count (19 patients, 9.6%). Most TRAEs were grade 1 and grade 2. TRAEs of grade \( \geq 3 \) occurred in only 23 (11.7%) patients, with the most common one being decreased white blood cell count (3 patients, 1.5%). There were two (1.0%) patients who had serious TRAE, including hypokalemia, pneumonia, and bone pain.

Treatment was interrupted in eight (4.1%) patients due to TRAEs (Additional file 1: Table S4). Dose reduction owing to TRAE was reported in only one (0.5%) patient (grade 2, neutrophil count decreased; grade 2, white blood cell count decreased). Three (1.5%) patients discontinued treatment owing to TRAEs, including
hypokalemia, bone pain, and anemia (each in one patient, 0.5%). No treatment-related deaths were reported.

**PK parameters**
A total of 41 patients were included for SHR3680 concentration analysis and 38 patients for PK parameter analysis at steady state. After a single dose administration, SHR3680 was rapidly absorbed, with a median time of maximum observed plasma concentration ($T_{\text{max}}$) of 2.0–18.0h. The exposure of SHR3680 increased in a dose-dependent manner, and decreased slowly, with a geomean terminal elimination half-life ($T_{1/2}$) of 76.7–89.6h (Additional file 1: Table S5). After multiple administration, the concentration of SHR3680 reached steady state after 15 days of daily treatment. The maximum observed plasma concentration ($C_{\text{max}}$) and area under the plasma concentration-time curve (AUC 0-24h) increased in a nearly dose-proportional manner from 40 mg to 240 mg per day dose range, but the increase of exposure was slow down between the 360mg to 480mg per day dose range (Additional file 1: Table S6).

**Efficacy**
At week 12, 134 (68.0%, 95% CI, 61.0–74.5) of the 197 patients achieved PSA response ($\geq$50% decrease in PSA). The PSA responses at week 12 were noted across all dose groups, and no obvious dose-dependent activity benefits were found (Table 3). The PSA responses at week 12 in patients with and without prior chemotherapy were 57.3% (95% CI, 45.9–68.2) and 75.7% (95% CI, 66.8–83.2), respectively (Additional file 1: Table S7); other subgroup analysis results are listed in Additional file 1: Table S8. Throughout the entire treatment course, proportion of patients with a maximum PSA decrease of $\geq$50% from baseline was 78.2% (95% CI, 71.7–83.7) and of $\geq$90% was 43.7% (95% CI, 36.6–50.9) (Table 3, Additional file 1: Table S7). Waterfall plots showed the PSA decrease at

| Table 1 | Baseline demographics and clinical characteristics |
|---------|--------------------------------------------------|
|         | 40 mg (N = 3) | 80 mg (N= 39) | 160 mg (N = 73) | 240 mg (N = 76) | 360 mg (N = 3) | 480 mg (N = 3) | Total (N = 197) |
| Age, years | | | | | | | |
| Median | 68 | 68 | 67 | 66 | 66 | 63 | 67 |
| Range | 66-77 | 45-80 | 54-80 | 49-79 | 66-79 | 58-71 | 45-80 |
| ECOG performance status | | | | | | | |
| 0 | 2 (66.7) | 13 (33.3) | 20 (27.4) | 26 (34.2) | 0 | 0 | 61 (31.0) |
| 1 | 1 (33.3) | 26 (66.7) | 53 (72.6) | 50 (65.8) | 3 (100) | 3 (100) | 136 (69.0) |
| Gleason score | | | | | | | |
| <9 | 2 (66.7) | 18 (46.2) | 43 (58.9) | 34 (44.7) | 1 (33.3) | 2 (66.7) | 100 (50.8) |
| $\geq$9 | 1 (33.3) | 14 (35.9) | 28 (38.4) | 37 (48.7) | 1 (33.3) | 1 (33.3) | 82 (41.6) |
| Unknown | 0 | 7 (17.9) | 2 (2.7) | 5 (6.6) | 1 (33.3) | 0 | 15 (7.6) |
| PSA (ng/mL) | | | | | | | |
| Median | 34.3 | 70.6 | 73.7 | 62.2 | 112.7 | 21.5 | 66.1 |
| Range | 9.7–36.8 | 2.7–2384.0 | 3.7–4796.0 | 3.3–3382.0 | 19.7–757.8 | 11.0–965.0 | 2.7–4796.0 |
| Alkaline phosphatase | | | | | | | |
| Normal | 3 (100) | 28 (71.8) | 56 (76.7) | 43 (56.6) | 1 (33.3) | 2 (66.7) | 133 (67.5) |
| Abnormal | 0 | 11 (28.2) | 17 (23.3) | 33 (43.4) | 2 (66.7) | 1 (33.3) | 64 (32.5) |
| Number of bone metastases | | | | | | | |
| $\leq$5 | 1 (33.3) | 12 (30.8) | 23 (31.5) | 24 (31.6) | 1 (33.3) | 1 (33.3) | 62 (31.5) |
| $>5$ | 2 (66.7) | 27 (69.2) | 50 (68.5) | 52 (68.4) | 2 (66.7) | 2 (66.7) | 135 (68.5) |
| Visceral metastases* | | | | | | | |
| Yes | 0 | 6 (15.4) | 13 (17.8) | 15 (19.7) | 1 (33.3) | 1 (33.3) | 36 (18.3) |
| No | 3 (100) | 33 (84.6) | 60 (82.2) | 61 (80.3) | 2 (66.7) | 2 (66.7) | 161 (81.7) |
| Prior treatment | | | | | | | |
| Surgery of primary tumor | 2 (66.7) | 12 (30.8) | 24 (32.9) | 19 (25.0) | 0 | 1 (33.3) | 58 (29.4) |
| Chemotherapy | 0 | 19 (48.7) | 29 (39.7) | 32 (42.1) | 0 | 2 (66.7) | 82 (41.6) |
| Radiotherapy | 1 (33.3) | 12 (30.8) | 18 (24.7) | 18 (23.7) | 0 | 1 (33.3) | 50 (25.4) |

Data are N (%), unless otherwise specified. * Metastasis to lymph node only are excluded. Abbreviations: ECOG Eastern Cooperative Oncology Group; PSA prostate-specific antigen.
week 12 and the maximum PSA decrease throughout treatment course (Fig. 2).

As of data cutoff, PSA progression events occurred in 113 (57.4%) patients. Median time to PSA progression was 8.3 months (95% CI, 5.6–11.0) in all patients, 8.3 months (95% CI, 4.8–13.8) in patients with prior chemotherapy, and 8.3 months (95% CI, 5.5–11.0) in patients without prior chemotherapy (Additional file 1: Figure S1). The two Kaplan-Meier curves for time to PSA progression in patients with and without prior chemotherapy overlapped during the study period without clear separation.

A total of 21 (34.4%, 22.7–47.7) of the 61 patients achieved a confirmed radiological objective response, including three (4.9%) patients with CR and 18 (29.5%) patients with PR (Table 3). The ORR in patients with prior chemotherapy was 20.8% (95% CI, 7.1–42.2) and in those without prior chemotherapy was 43.2% (95% CI, 27.1–60.5; Additional file 1: Table S9). The number of patients who had a disease control was 53 (86.9%, 95% CI, 75.8–94.2). Bone scan at week 12 revealed that 174 (88.3%; 95% CI, 87.2–95.5) patients had stable disease in bone, including 69 (84.1%; 95% CI, 78.0–93.8) with prior chemotherapy and 105 (91.3%; 95% CI, 89.7–98.5) without prior chemotherapy.

### Table 2: Treatment-related adverse events

|                     | All patients (N = 197) |
|---------------------|------------------------|
|                     | Any grade | Grade ≥3 |
| Any                 | 116 (58.9) | 23 (11.7) |
| Proteinuria         | 27 (13.7)  | 0         |
| Hot flush           | 22 (11.2)  | 0         |
| White blood count decreased | 19 (9.6)  | 3 (1.5)  |
| Neutrophil count decreased | 14 (7.1)  | 2 (1.0)  |
| Astenia             | 13 (6.6)   | 0         |
| Occult blood positive | 12 (6.1)  | 0         |
| Aspartate aminotransferase increased | 12 (6.1)  | 0         |
| Bilirubin conjugated increased | 11 (5.6)   | 0         |
| Platelet count decreased | 10 (5.1)  | 0         |
| Alanine aminotransferase increased | 9 (4.6)    | 1 (0.5)  |
| Blood thyroid stimulating hormone increased | 8 (4.1)    | 0         |
| Hypertiglyceridemia | 7 (3.6)    | 1 (0.5)  |
| Decreased appetite  | 7 (3.6)    | 1 (0.5)  |
| Hypertension        | 7 (3.6)    | 2 (1.0)  |
| Gynecomastia        | 7 (3.6)    | 1 (0.5)  |
| Anemia              | 7 (3.6)    | 1 (0.5)  |

Data are N (%). Treatment-related adverse events of any grade occurring in ≥3% of total patients are listed.

### Table 3: Study endpoints related to response

| PSA response | 40 mg (N = 3) | 80 mg (N = 39) | 160 mg (N = 73) | 240 mg (N = 76) | 360 mg (N = 3) | 480 mg (N = 3) | Total (N = 197) |
|--------------|---------------|----------------|-----------------|-----------------|---------------|---------------|-----------------|
| At week 12   | 2 (66.7, 9.4-99.2) | 25 (64.1, 47.2-78.8) | 51 (69.9, 58.0-80.1) | 51 (67.1, 55.4-77.5) | 2 (66.7, 9.4-99.2) | 3 (100, 29.2-100) | 134 (68.0, 61.0-74.5) |
| Maximum PSA decrease from baseline ≥50% | 3 (100, 29.2-100) | 28 (71.8, 55.1-85.0) | 61 (83.6, 73.0-91.2) | 57 (75.0, 63.7-84.2) | 2 (66.7, 9.4-99.2) | 3 (100, 29.2-100) | 154 (78.2, 71.7-83.7) |
| ≥90% | 2 (66.7, 9.4-99.2) | 16 (41.0, 25.6-57.9) | 32 (43.8, 32.2-55.9) | 32 (42.1, 30.9-54.0) | 1 (33.3, 0.8-90.6) | 3 (100, 29.2-100) | 86 (43.7, 36.6-50.9) |

| Radiological response | 40 mg (N = 3) | 80 mg (N = 39) | 160 mg (N = 73) | 240 mg (N = 76) | 360 mg (N = 3) | 480 mg (N = 3) | Total (N = 197) |
|-----------------------|---------------|----------------|-----------------|-----------------|---------------|---------------|-----------------|
| CR                    | 0             | 1 (9.1)        | 0               | 2 (7.7)         | 0             | 0             | 3 (4.9)         |
| PR                    | 0             | 2 (18.2)       | 6 (31.6)        | 8 (30.8)        | 1 (33.3)      | 1 (100.0)     | 18 (29.5)       |
| SD                    | 1 (100.0)     | 4 (36.4)       | 13 (68.4)       | 12 (46.2)       | 2 (66.7)      | 0             | 32 (52.5)       |
| PD                    | 0             | 3 (27.3)       | 0               | 3 (11.5)        | 0             | 0             | 6 (9.8)         |
| NE                    | 0             | 1 (9.1)        | 0               | 1 (3.8)         | 0             | 0             | 2 (3.3)         |
| Objective response    | 0 (0, 0-97.5) | 3 (27.3, 60.0-61.0) | 6 (31.6, 12.6-56.6) | 10 (38.5, 20.2-59.4) | 1 (33.3, 0.8-90.6) | 1 (100.0) | 21 (34.4, 22.7-47.7) |
| Disease control       | 1 (100, 2.5-100) | 7 (63.6, 30.8-89.1) | 19 (100, 82.4-100) | 22 (84.6, 65.1-95.6) | 3 (100, 29.2-100) | 1 (100.0) | 53 (86.9, 75.8-94.2) |
| Stable disease in bone at week 12 | 3 (100, 29.2-100) | 35 (89.7, 85.5-99.9) | 66 (90.4, 81.2-96.1) | 64 (84.2, 80.7-95.9) | 3 (100, 29.2-100) | 3 (100, 29.2-100) | 174 (88.3, 87.2-95.5) |

Data are N (%), 95% CI) or N (%). Abbreviations: PSA prostate-specific antigen; CR complete response; PR partial response; SD stable disease; PD progressive disease; NE not evaluable.
Ninety-seven (49.2%) patients had PFS events (radiological progression or death) by the time of data cut-off. The median radiological PFS was 14.0 months (95% CI, 11.1–19.5; Fig. 3A). For patients with prior chemotherapy and those without prior chemotherapy, median radiological PFS was 11.1 months (95% CI, 8.3–19.4) and 19.5 months (95% CI, 11.1–27.6), respectively (Fig. 3A). As of data cutoff, 91 (46.2%) patients died. The median overall survival was 27.5 months (95% CI, 24.6–30.8; Fig. 3B). Subgroup analyses further indicated that patients with normal baseline alkaline phosphatase level, Gleason score < 9, or disease duration > 2 years had a relatively longer median PFS and OS (Additional file 1: Figure S2 and Figure S3).

**Discussion**

We reported here the results of the first-in-human phase 1/2 study of a novel AR antagonist SHR3680, which has a lower distribution in the brain and decreased risk to induce seizure than enzalutamide as revealed in animal
The results showed that SHR3680 was well-tolerant and safe in patients with metastatic CRPC, with promising anti-tumor activity.

In the dose-escalation phase 1 portion, no DLT event occurred in any dose group ranging from 40 mg to 480 mg per day, indicating a high tolerability of SHR3680. Of note, the drug exposure of SHR3680 in 160 mg per day dose group was equivalent to that of enzalutamide in 360 mg per day dose group ($C_{\text{max}}$, 23.9 μg/mL vs 25.1 μg/mL; AUC$_{0-\tau}$, 459 μg*h/mL vs 502 μg*h/mL), and the drug exposure of SHR3680 in 480 mg per day group was about twice that of SHR3680 160 mg per day group ($C_{\text{max}}$, 49.7 μg/mL vs 25.1 μg/mL; AUC$_{0-\tau}$, 976 μg*h/mL vs 502 μg*h/mL) [12]. Considering that the preclinical anti-tumor activity of SHR3680 was comparable to that of enzalutamide and the MTD of enzalutamide was 240 mg per day [7], a higher dose for escalation was not considered in our study.

The safety profile of SHR3680 was favorable and similar with that of enzalutamide [7]. Only 11.7% of patients had grade $\geq 3$ TRAEs, and 1.0% of patients had serious TRAEs. The incidence of TRAE was not dose-dependent. In 360 mg and 480 mg per day dose groups, despite long
duration of drug exposure (mean 22.1 and 23.6 months, respectively), no new safety signals were identified.

None of the 197 patients received SHR3680 treatment in this study reported any grade of seizure. In the phase 1/2 study of enzalutamide, seizure occurred in three patients (each in 360 mg, 480 mg, and 600 mg per day group). In the phase 3 AFFIRM trial, although patients who had a risk of seizure were excluded, the incidence of seizures in the enzalutamide 160 mg per day group was still 0.9%, while no seizure occurred in placebo group [7, 8, 13]. Therefore, consistent with the results of preclinical studies (data on file, Hengrui), this study strongly supported the advantage of SHR3680 in reducing the risk of seizure compared with similar drugs.

Fatigue is another frequent and potential AE of AR antagonist. In the phase 1/2 study of enzalutamide, grade 3–4 fatigue occurred in 11% (16/140) of patients; of them, one patient discontinued enzalutamide treatment due to fatigue [7]. In our study, no grade 3–4 fatigue was reported, and no dose reduction, treatment interruption, or treatment discontinuation were induced by fatigue.

In patients without previous chemotherapy, the PSA response rate at week 12 of SHR3680 was 75.7%, which was comparable to that of apalutamide (48.0–88.0%) and darolutamide (65.5–83.3%) in studies which had similar inclusion criteria and baseline clinical characteristics as our study [14–18]. In patients with a history of chemotherapy, the PSA response rate at week 12 was 57.3% and was numerically higher than that of darolutamide (32.3%) [14].

Conclusions
SHR3680 was well tolerated and safe in patients with metastatic CRPC. It had encouraging efficacy in PSA reduction and anti-tumor activity in patients with or without prior chemotherapy. The results of this study supported further investigation of SHR3680, at a planned dose of 240 mg per day, in a randomized controlled phase 3 trial (NCT03520478) in patients with metastatic hormone sensitive prostate cancer.

Abbreviations
AE: Adverse event; AR: Androgen receptor; CR: Complete response; CRPC: Castration-resistant prostate cancer; DCR: Disease control rate; DLT: Dose-limiting toxicity; ECOG: Eastern Cooperative Oncology Group; GABAa: γ-Aminobutyric acid; MTD: Maximum tolerable dose; ORR: Objective response rate; OS: Overall survival; PCWG2: Prostate Cancer Working Group; PFS: Progression-free survival; PK: Pharmacokinetics; PR: Partial response; PSA: Prostate-specific antigen; RECIST: Response Evaluation Criteria in Solid Tumors; TFST: Time to first subsequent therapy; TRAE: Treatment-related adverse event.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12916-022-02263-x.

Acknowledgements
We thank all patients and their families and acknowledge the contributions of all investigators in this trial. We would also like to acknowledge Tengfei Zhang (PhD, Medical Writer, Jiangsu Hengrui Pharmaceuticals Co., Ltd.) for medical writing support according to Good Publication Practice Guidelines.

Prior presentation
Part of the results had been presented as a poster in 2020 Genitourinary Cancers Symposium of ASCO. This manuscript has not been published or presented elsewhere in entirety.

Authors’ contributions
CJ, JZ, and DY designed the study; XQ, DJ, WG, WH, HL, CD, QZ, ZS, CH, SZ, TC, XY1 (Xin Yao), BW, AB, CJ, JZ, and DY conducted the study and collected data; XY2 (Xinfeng Yang) and AB analyzed the data; DY, XQ, DJ, and WG wrote and revised the manuscript. All authors read and approved the final manuscript.

Funding
This study was supported by Jiangsu Hengrui Pharmaceuticals Co., Ltd.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
Declarations

Ethics approval and consent to participate
The study was done in accordance with Declaration of Helsinki and the Good Clinical Practice Guideline. The protocol and all amendments were approved by the institutional review board or independent ethics committee of each study site (Fudan University Shanghai Cancer Center, Hunan Cancer Hospital, Chongqing Cancer Hospital, The Second Affiliated Hospital of Zhejiang University School of Medicine, Jiangsu Cancer Hospital, Huadong Hospital Affiliated to Fudan University, Cancer Hospital of Henan Province, Zhejiang Cancer Hospital, The Second Affiliated Hospital of Xi’an Jiaotong University, Tianjin Cancer Hospital, and Beijing Hospital). All patients provided written informed consent.

Consent for publication
Not applicable.

Competing interests
Xinfeng Yang, Aobing Bai, Chunlei Jin, and Jianjun Zou are employees of Jiangsu Hengrui Pharmaceuticals Co., Ltd. Other co-authors declare no competing interests.

Author details
1 Department of Urology, Fudan University Shanghai Cancer Center, 270 Dong’an Road, Shanghai 200032, China. 2 Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China. 3 Department of Urology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Hunan Cancer Center, Changsha, China. 4 Department of Urology, Chongqing University Cancer Hospital, Chongqing Cancer Hospital, Chongqing, China. 5 Department of Urology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China. 6 Department of Urology, Huadong Hospital Affiliated to Fudan University, Shanghai, China. 7 Department of Urology, The Second Affiliated Hospital of Xian Jiaotong University, Xian, China. 8 Department of Urology, Tianjin Medical University Cancer Institute & Hospital, Tianjin, China. 9 Department of Urology, Zhejiang Cancer Hospital, Hangzhou, China. 10 Department of Medical Oncology, The Affiliated Cancer Hospital of Xi’an Jiaotong University, Tianjin, China. 11 Department of Clinical Development, Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, China.

Received: 15 November 2021   Accepted: 18 January 2022
Published online: 04 March 2022

References
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(1):10–33.
2. NCCN. Clinical Practice Guidelines in Oncology. Prostate cancer: Version 2, 2021. https://www.nccn.orgprofessionals/physician_gls/pdf/prostate.pdf [Accessed 19 March 2021].
3. Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol. 2005;23(32):8353–61.
4. Massard C, Fizazi K. Targeting continued androgen receptor signaling in prostate cancer. Clin Cancer Res. 2011;17(12):3876–83.
5. Egan A, Dong Y, Zhang H, Qi Y, Balk SP, Sartor O. Castration-resistant prostate cancer: adaptive responses in the androgen axis. Cancer Treat Rev. 2014;40(3):426–33.
6. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009;324(5928):787–90.
7. Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study. Lancet. 2010;375(9724):1437–46.
8. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187–97.
9. Chi KN, Agarwal N, Bjartell A, Chung BH, de Santana P, Gomes AJ, et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med. 2019;381(1):13–24.
10. Foster WN, Car BD, Shi H, Levesque PC, Obermeier MT, Gan J, et al. Drug safety is a barrier to the discovery and development of new androgen receptor antagonists. Prostate. 2011;71(5):480–8.
11. Rathkopf D, Liu G, Carducci MA, Eisenberger MA, Anand A, Morris MI, et al. Phase I dose-escalation study of the novel antiandrogen BMS-641988 in patients with castration-resistant prostate cancer. Clin Cancer Res. 2011;17(4):880–7.
12. Gibbons JA, de Vries M, Krauwinkel W, Ohtsu Y, Noukens J, van der Walt JS, et al. Pharmacokinetic drug interaction studies with enzalutamide. Clin Pharmacokinet. 2015;54(10):1057–69.
13. Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371(5):424–33.
14. Fizazi K, Massard C, Bono P, Jones R, Kataja V, James N, et al. Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial. Lancet Oncol. 2014;15(9):975–85.
15. Rathkopf DE, Antonarakis ES, Shore ND, Tutrone RF, Alumkal J, Ryan CJ, et al. Safety and antitumour activity of apalutamide (ARN-509) in metastatic castration-resistant prostate cancer with and without prior abiraterone-acetate and prednisone. Clin Cancer Res. 2017;23(14):3544–51.
16. Rathkopf DE, Morris MJ, Fox JJ, Danila DC, Slvin SF, Hager JH, et al. Phase I study of ARN-509, a novel antitumour, in the treatment of castration-resistant prostate cancer. J Clin Oncol. 2013;31(28):3525–30.
17. Shore ND, Tammela TL, Massard C, Bono P, Aspegren J, Mustonen M, et al. Safety and antitumour activity of ODM-201 (BAY-1841788) in chemotherapy-naive and CYP17 inhibitor-naive patients: follow-up from the ARADES and ARAFOR trials. Eur Urol Focus. 2018;4(4):547–53.
18. Massard C, Penttinen HM, Väners E, Bono P, Lietusvietis V, Tammela TL, et al. Pharmacokinetics, antitumour activity, and safety of ODM-201 in patients with chemotherapy-naive metastatic castration-resistant prostate cancer: an open-label phase 1 study. Eur Urol. 2016;69(5):834–40.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.